Exercise capacity in sarcoidosis. Study of 29 patients
- PMID: 15899162
- DOI: 10.1157/13075090
Exercise capacity in sarcoidosis. Study of 29 patients
Abstract
Background and objective: Sarcoidosis is a systemic granulomatous disease of unknown etiology. Aims of this prospective study are to evaluate degree of impairment in pulmonary function tests (PFT), arterial blood gas analysis (ABG), respiratory muscle strength, exercise capacity and correlation of these parameters with radiological stages; to further evaluate the use of cardiopulmonary exercise testing in assessment of extent of pulmonary disease; and to discuss the pathophysiologic mechanisms of limitation in exercise capacity in patients with sarcoidosis.
Patients and method: 29 patients with sarcoidosis were grouped according to their radiological stages (stage I: group 1; stage II, group 2; stage III, group 3). Groups 1, 2 and 3 included 11, 13 and 5 patients, respectively. PFT, cardiopulmonary exercise testing and ABG were performed for each patient.
Results: Evaluation of all patients showed a significant decrement in exercise capacity. Patients in stage III had decreased diffusing capacity and exercise capacity. There was limitation in exercise capacity in stage I patients who had completely normal spirometry and diffusing capacity. We also found a correlation between radiological stages of the disease and exercise capacity, diffusing capacity and ABG.
Conclusions: Exercise capacity is impaired also in early stages of sarcoidosis and it was found to be the earliest impaired physiological parameter in sarcoid patients. Exercise intolerance, having mutifactorial basis, is correlated with radiological stages. Circulatory impairment and impaired heart rate response to exercise have effects on limitation in exercise capacity. Especially in advanced radiological stages of disease, ventilatory and gas exchange impairment also seems to be effective on limiting exercise in patients with sarcoidosis.
Similar articles
-
Reduction of exercise capacity in sarcoidosis in relation to disease severity.Patient Prefer Adherence. 2015 Aug 18;9:1179-88. doi: 10.2147/PPA.S86465. eCollection 2015. Patient Prefer Adherence. 2015. PMID: 26316723 Free PMC article.
-
Spirometry, cardiopulmonary exercise testing and the six-minute walk test results in sarcoidosis patients.Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(3):185-194. doi: 10.36141/svdld.v36i3.7663. Epub 2019 May 1. Sarcoidosis Vasc Diffuse Lung Dis. 2019. PMID: 32476953 Free PMC article.
-
Reduction of maximal oxygen uptake in sarcoidosis: relationship with disease severity.Respiration. 2011;82(6):501-8. doi: 10.1159/000330050. Epub 2011 Sep 20. Respiration. 2011. PMID: 21934275
-
Clinical presentation of sarcoidosis and diagnostic work-up.Semin Respir Crit Care Med. 2014 Jun;35(3):336-51. doi: 10.1055/s-0034-1381229. Epub 2014 Jul 9. Semin Respir Crit Care Med. 2014. PMID: 25007086 Review.
-
Pulmonary Sarcoidosis.Clin Chest Med. 2015 Dec;36(4):631-41. doi: 10.1016/j.ccm.2015.08.006. Clin Chest Med. 2015. PMID: 26593138 Review.
Cited by
-
Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency.Eur Respir Rev. 2021 Nov 30;30(162):200355. doi: 10.1183/16000617.0355-2020. Print 2021 Dec 31. Eur Respir Rev. 2021. PMID: 34853093 Free PMC article. Review.
-
Reduction of exercise capacity in sarcoidosis in relation to disease severity.Patient Prefer Adherence. 2015 Aug 18;9:1179-88. doi: 10.2147/PPA.S86465. eCollection 2015. Patient Prefer Adherence. 2015. PMID: 26316723 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources